Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151597 in advanced retinitis pigmentosa
NCT02556736Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2015
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of RST-001 in retinitis pigmentosa (RP), sponsored by AbbVie Inc.. Started Dec 2015; status: completed.
02
Drugs
RST-001
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT02556736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556736.